Please use this identifier to cite or link to this item: https://covid-19.conacyt.mx/jspui/handle/1000/2222
Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro.
Norio Yamamoto.
Shutoku Matsuyama.
Tyuji Hoshino.
Naoki Yamamoto.
Acceso Abierto
Atribución-NoComercial-SinDerivadas
10.1101/2020.04.06.026476
In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, Hubei Province, China. No specific treatment has been established against coronavirus disease-2019 (COVID-19) so far. Therefore, it is urgently needed to identify effective antiviral agents for the treatment of this disease, and several approved drugs such as lopinavir have been evaluated. Here, we report that nelfinavir, an HIV-1 protease inhibitor, potently inhibits replication of SARS-CoV-2. The effective concentrations for 50% and 90% inhibition (EC50 and EC90) of nelfinavir were 1.13 {micro}M and 1.76 {micro}M respectively, the lowest of the nine HIV-1 protease inhibitors including lopinavir. The trough and peak serum concentrations of nelfinavir were three to six times higher than EC50 of this drug. These results suggest that nelfinavir is a potential candidate drug for the treatment of COVID-19 and should be assessed in patients with COVID-19.
www.biorxiv.org
2020
Artículo
https://www.biorxiv.org/content/10.1101/2020.04.06.026476v1.full.pdf
Inglés
VIRUS RESPIRATORIOS
Appears in Collections:Artículos científicos

Upload archives


File SizeFormat 
1101294.pdf180.01 kBAdobe PDFView/Open